Research

Doctor Worked To Treat Blot Clot In Space

Share

A check-up soon after landing revealed that spontaneous blood flow had returned to the affected vein, and the clot itself faded away 10 days after their return to Earth; six months later, the astronaut appeared to be completely recovered.

The clot was the first of any to be found in space, and was discovered when the astronaut took an ultrasound of their neck as part of a research study to examine how body fluid is redistributed under zero gravity conditions.

"In this space case, the power of telemedicine from a room on the International Space Station to the doctor's office on Earth is sensational", he said.

For privacy reasons, the name of the astronaut and other details have been withheld, though they were two months into a six-month mission.

It would lead to the International Space Station, where an astronaut had a blood clot.

Moll and NASA scientists have asked for more research on blood clots in space, including treatments and possible preventive measures.

A (momentarily) unidentified astronaut who is aboard the ISS (International Space Station) suffered a deep vein thrombosis (DVT) - commonly known as a blood clot - in the jugular vein (of the neck), a new case study reports. He was the only non-NASA expert considered for the treatment. The astronaut took a higher dose of the injectable, enoxaparin, for 33 days to control the risk of the blood clot.

They exclusively had an injection primarily based model of the drug they determined to make use of - Enoxaparin - on board the station and exclusively sufficient to final 40 days on the dosage prescribed by Dr Moll.

"If it wasn't for the study, there's no telling what the outcome could have been", said Dr Moll, who is now working with NASA on detection and treatment of blood clots.

Moll is a star when it comes to his blood clot expertise, having been published in medical journals.

They only had an injection based version of the drug they chose to use - Enoxaparin - on board the station and only enough to last 40 days at the dosage prescribed by Dr Moll. The team in space had only a limited supply of blood thinners, which needed to be delivered via syringes-yet another precious commodity in space. Three days after stocks of the blood thinner ran out, a shipment of Apixaban, which is in pill form, arrived by spacecraft, allowing the treatment to extend to a total of over 90 days. Moll was also able to speak to the astronaut during this period through email and phone calls.

The Worldwide House Station (ISS) is a $100 billion (£80 billion) science and engineering laboratory that orbits 250 miles (400 km) above Earth.

"Is this something that is more common in space?" posed Moll.

The astronaut landed safely on Earth and the blood clot didn't require any further treatment.

It's now imperative that research continue into "the development of prevention and management strategies for venous thromboembolism in weightlessness, especially with future plans for prolonged space travel to the moon and Mars", the team wrote. The team of doctors decided that space travel is risky enough and physically demanding, they didn't want to take a chance. Should there be more medications to keep in the ISS?

Share